Who is sponsoring NCT03582514?

NCT03582514 is sponsored by The Christie NHS Foundation Trust.

What drugs are being tested in NCT03582514?

Interventions in NCT03582514: Preoperative brain irradiation (single fraction).

What condition does NCT03582514 study?

NCT03582514 studies Glioblastoma Multiforme.

Is NCT03582514 still recruiting?

NCT03582514 is currently status unknown. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT03582514: POBIG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PreOperative Brain Irradiation in Glioblastoma

Status unknown Phase 1 Last updated 18 November 2023

What this trial tests

Phase 1 trial testing Preoperative brain irradiation (single fraction) in Glioblastoma Multiforme in 18 participants. Status unknown.

Timeline

19 April 2022

Primary endpoint
30 June 2025

30 June 2025

Quick facts

Lead sponsor	The Christie NHS Foundation Trust
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	19 April 2022
Primary completion	30 June 2025
Estimated completion	30 June 2025
Sites	1 location across United Kingdom

Drugs / interventions tested

Preoperative brain irradiation (single fraction)

Conditions studied

Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →

Sponsor

The Christie NHS Foundation Trust

Who can join

18 and older, any sex, with Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PreOperative Brain Irradiation in Glioblastoma (POBIG) is a phase I study that will test the safety and feasibility of a single fraction of preoperative radiotherapy in patients with a new radiological diagnosis of glioblastoma (GBM). After the single fraction of radiotherapy, patients will receive standard treatment. The standard treatment consists of resection of the tumor followed by (chemo)radiation (i.e. radiotherapy +/- daily temozolomide (75mg/m2) for 6 weeks (60Gy/30fr) or for 3 weeks (40Gy/15fr)).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Early Therapeutic Interventions for Newly Diagnosed Glioblastoma: Rationale and Review of the Literature.
Waqar M, Trifiletti DM, McBain C, O'Connor J, et al · · 2022 · cited 27× · PMID 35119629 · DOI 10.1007/s11912-021-01157-0
Visualising spatial heterogeneity in glioblastoma using imaging habitats.
Waqar M, Van Houdt PJ, Hessen E, Li KL, et al · · 2022 · cited 22× · PMID 36505856 · DOI 10.3389/fonc.2022.1037896
Study protocol: PreOperative Brain Irradiation in Glioblastoma (POBIG) - A phase I trial.
Waqar M, Roncaroli F, Djoukhadar I, Akkari L, et al · · 2023 · cited 9× · PMID 36845633 · DOI 10.1016/j.ctro.2023.100585
Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma.
Wisdom AJ, Temple H, Cui Y, Del Vecchio CT, et al · · 2026 · PMID 42031225 · DOI 10.1016/j.ijrobp.2026.04.013

Verify or expand the search:

Other recruiting trials for Glioblastoma Multiforme

Currently open trials in the same condition.

NCT06466031 — Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] · NA · recruiting
NCT06333899 — Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · EARLY_PHASE1 · recruiting
NCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age · Phase 1, PHASE2 · recruiting
NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
NCT06329570 — Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multif · Phase 1, PHASE2 · recruiting

Other The Christie NHS Foundation Trust trials

Trials by the same sponsor.

NCT07183267 — Using Red Light Therapy to Ease Skin Side Effects and Mouth Side Effects, in Children and Young People Aged 0 to 16 Year · NA · not yet recruiting
NCT07268339 — A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calme · Phase 3 · not yet recruiting
NCT06965101 — To Determine Whether it is Feasible to Treat Patients Requiring Urgent Radiotherapy Diagnosed With Metastatic Cord Compr · NA · recruiting
NCT05903430 — A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION) · recruiting
NCT07202260 — Pragmatic Analysis of Complex Radiotherapy Cases In Cancer of the Lung · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03582514 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Christie NHS Foundation Trust
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03582514.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing